Healthy Volunteers Clinical Trial
Official title:
A Phase I, Single-Center, Open-label, Single Dose Pharmacokinetic and Tolerability Study of GZ402671 in Subjects With Mild, Moderate and Severe Renal Impairment, and in Matched Subjects With Normal Renal Function
Verified date | April 2022 |
Source | Sanofi |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Primary Objective: To study the effect of mild, moderate and severe renal impairment on the pharmacokinetics (PK) of Venglustat following a single dose. Secondary Objective: To assess the tolerability of Venglustat given as a single dose in subjects with mild, moderate and severe renal impairment in comparison with matched subjects with normal renal function.
Status | Completed |
Enrollment | 24 |
Est. completion date | February 27, 2019 |
Est. primary completion date | February 27, 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 79 Years |
Eligibility | Inclusion criteria: For all Subjects: - Male and/or female subjects, between 18 and 79 years of age, inclusive. - Body weight between 50.0 and 115.0 kg, inclusive, if male, and between 40.0 and 100.0 kg, inclusive, if female, body mass index between 18.0 and 34.9 kg/m2, inclusive - Normal electrocardiogram (ECG) - Having given written informed consent prior to undertaking any study-related procedure - Not under any administrative or legal supervision - Male subject, whose partners are of childbearing potential (including lactating women), must accept to use, during sexual intercourse, a double contraception method according to the following algorithm: (condom) plus (spermicide or intra-uterine device or hormonal contraceptive) from the inclusion up to 4 months after the last dosing - Male subject, whose partners are pregnant, must use, during sexual intercourse, a condom from the inclusion up to 4 months after the last dosing - Male subject has agreed not to donate sperm from the inclusion up to 4 months after the last dosing - Female subject must use a double contraception method including a highly effective method of birth control from at least 30 days prior to the inclusion to 30 days after the last IMP administration, except if she has undergone sterilization (documented) at least 3 months earlier or is postmenopausal Specific for subjects with renal impairment: - Stable chronic renal impairment - Vital signs and laboratory parameters within acceptable range for subjects with renal impairment Specific for matched healthy subjects: - Normal renal function - Certified as healthy by a comprehensive clinical assessment (detailed medical history and complete physical exam) - Normal vital signs and laboratory parameters Exclusion criteria: - Frequent headaches and/or migraine, recurrent nausea and/or vomiting (for vomiting only: more than twice a month) - Blood donation, any volume, within 2 months before inclusion - Symptomatic postural hypotension, irrespective of the decrease in blood pressure, or asymptomatic postural hypotension judged clinically relevant by the Investigator - Any significant change in chronic treatment medication within 14 days before inclusion - Any drug which could impact by any mechanism of action, the pharmacokinetics of the investigational medicinal product, including moderate and strong cytochrome P3A (CYP3A) inhibitors or inducers; any vaccination within the last 28 days and any biologics (antibody or its derivatives) given within 4 months before inclusion - Positive result on any of the following tests: hepatitis B surface (HBs Ag) antigen, anti-hepatitis C virus (anti-HCV) antibodies, anti-human immunodeficiency virus 1 and 2 antibodies (anti-HIV1 and anti HIV2 Ab) - Positive result on urine drug screen or plasma alcohol test - Active hepatitis, hepatic insufficiency - If female, pregnancy [defined as positive ß-Human Chorionic Gonadotropin (ß-HCG) blood test], breast-feeding Specific for subjects with renal impairment: - Uncontrolled clinically relevant cardiovascular, pulmonary, gastrointestinal, metabolic, hematological, neurological, osteomuscular, articular, psychiatric, systemic, ocular, or infectious disease, or signs of acute illness - Acute renal failure (de novo or superimposed on preexisting chronic renal impairment), nephrotic syndrome - History of or current hematuria of urologic origin that limits the subject's participation in the study - Subjects requiring dialysis during the study Specific for matched healthy controls: - Any history or presence of clinically relevant cardiovascular, pulmonary, gastrointestinal, hepatic, renal, metabolic, hematological, neurological, osteomuscular, articular, psychiatric, systemic, ocular, gynecologic (if female) or infectious disease, or signs of acute illness The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial. |
Country | Name | City | State |
---|---|---|---|
United States | Investigational Site Number 8400001 | Miami | Florida |
Lead Sponsor | Collaborator |
---|---|
Genzyme, a Sanofi Company |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Assessment of pharmacokinetic (PK) parameters of Venglustat: Area under the curve (AUC) | Venglustat area under the plasma concentration versus time curve (AUC) | Day 1 to Day 10 | |
Secondary | Venglustat plasma pharmacokinetic (PK) parameter: Cmax | Maximum plasma concentration observed (Cmax) | Day 1 | |
Secondary | Venglustat plasma pharmacokinetic (PK) parameter: AUClast | Area under the plasma concentration versus time curve calculated from time zero to the real time tlast (AUClast) | Day 1 to Day 10 | |
Secondary | Venglustat plasma pharmacokinetic (PK) parameter: unbound Cmax | Maximum plasma concentration observed of unbound drug (unbound Cmax) | Day 1 to Day 10 | |
Secondary | Venglustat plasma pharmacokinetic (PK) parameter: unbound AUC | Change in unbound Venglustat area under the plasma concentration versus time curve (unbound AUC) | Day 1 to Day 10 | |
Secondary | Venglustat plasma pharmacokinetic (PK) parameter: CL/F | Apparent total body clearance of Venglustat from plasma (CL/F) | Day 1 to Day 10 | |
Secondary | Venglustat plasma pharmacokinetic (PK) parameter: Vss/F | Apparent volume of distribution of Venglustat at steady state (Vss/F) | Day 1 to Day 10 | |
Secondary | Venglustat plasma pharmacokinetic (PK) parameter: fu | Fraction of unbound venglustat in plasma (fu) | Day 1 to Day 10 | |
Secondary | Venglustat plasma pharmacokinetic (PK) parameter: t1/2z | Terminal half-life associated with the terminal slope (t1/2z) | Day 1 to Day 10 | |
Secondary | Venglustat plasma pharmacokinetic (PK) parameter: t1/2eff | Effective half-life (t1/2eff) | Day 1 to Day 10 | |
Secondary | Venglustat urine pharmacokinetic (PK) parameter: Ae(0-24) | Cumulated amount excreted in urine from time 0 to time 24h after Venglustat administration | Day 1 and Day 2 | |
Secondary | Venglustat urine pharmacokinetic (PK) parameter: fe(0-24) | Fraction of dose excreted in urine from time 0 to time 24h after Venglustat administration | Day 1 and Day 2 | |
Secondary | Venglustat urine pharmacokinetic (PK) parameter: CLR(0-24) | Renal clearance of the drug determined in the 0-24h interval (CLR(0-24)) | Day 1 and Day 2 | |
Secondary | Venglustat plasma pharmacokinetic (PK) parameter: Rac,pred | Predicted accumulation ratio (Rac,pred) | Day 1 to Day 10 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05029518 -
3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability
|
Phase 1 | |
Completed |
NCT05001152 -
Taste Assessment of Ozanimod
|
Phase 1 | |
Completed |
NCT04493255 -
A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants
|
Phase 1 | |
Completed |
NCT03457649 -
IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00995891 -
Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
|
||
Completed |
NCT05050318 -
Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively
|
Phase 4 | |
Completed |
NCT05043766 -
Evaluation of Oral PF614 Relative to OxyContin
|
Phase 1 | |
Completed |
NCT04466748 -
A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects
|
Phase 1 | |
Completed |
NCT00746733 -
Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC
|
Phase 1 | |
Recruiting |
NCT05929651 -
Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy
|
Phase 4 | |
Completed |
NCT05954039 -
Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect
|
N/A | |
Completed |
NCT05045716 -
A Study of Subcutaneous Lecanemab in Healthy Participants
|
Phase 1 | |
Active, not recruiting |
NCT02747927 -
Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children
|
Phase 3 | |
Completed |
NCT05533801 -
A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants
|
Phase 1 | |
Not yet recruiting |
NCT03931369 -
Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST)
|
Phase 2 | |
Completed |
NCT03279146 -
A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects
|
Phase 1 | |
Completed |
NCT06027437 -
A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants
|
Phase 1 | |
Recruiting |
NCT05619874 -
Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity
|
N/A | |
Completed |
NCT05553418 -
Investigational On-body Injector Clinical Study
|
N/A | |
Completed |
NCT04092712 -
Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers
|
Phase 1 |